Israel Englander Gt Biopharma, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.22 - $0.28 $37,158 - $47,293	-168,904 Reduced 71.92%	65,953 $17,000
Q2 2023 Aug 14, 2023	BUY	$0.22 - $0.55 $20,224 - $50,561	91,930 Added 64.32%	234,857 $72,000
Q1 2023 May 15, 2023	BUY	$0.46 - $1.05 $5,070 - $11,573	11,022 Added 8.36%	142,927 $79,000
Q4 2022 Feb 14, 2023	SELL	$0.89 - $58.2 $19,645 - $1.28 Million	-22,074 Reduced 14.34%	131,905 $118,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $56.1 $163,263 - $5.06 Million	-90,201 Reduced 36.94%	153,979 $271,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.1M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.